Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension

References

• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Committee. Circulation 2009;119:e21-181. Available at: http://circ.ahajournals.org/cgi/reprint/119/2/e21. [Last accessed 30 November 2009]
   Google Scholar
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services; 2004. NIH Publication No. 04-5230. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. [Last accessed 30 November 2009]
   Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2009. Diabetes Care 2009;32(Suppl 1):S13-61
   PubMedGoogle Scholar
• National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49(Suppl 2):S46
   Google Scholar
• Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75
   PubMed Web of Science ®Google Scholar
• Elliott W, Plauschinat C, Skrepnek G, et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20:72-80
   PubMed Web of Science ®Google Scholar
• Heran BS, Wong MMY, Heran IK, et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Syst Rev 2008, Issue 4. Art. No.: CD003822. DOI: 10.1002/14651858.CD003822.pub2
   Google Scholar
• Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91
   PubMedGoogle Scholar
• Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001;19(Suppl 1):S49-56
   Google Scholar
• Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens 2007;9:187-95
   PubMedGoogle Scholar
• Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12(4 Pt 1):414-17
   Web of Science ®Google Scholar
• Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998;11(4 Pt 1):445-53
   Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, DeZeeuw, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Anderson AN, Wessels F, Moodley I, et al. AT1 receptor blockers – cost-effectiveness within the South African context. A Afr Med J 2000;90:494-8
   PubMed Web of Science ®Google Scholar
• Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. Pharmacoeconomics 2003;21:61-74
   PubMed Web of Science ®Google Scholar
• Boersma C, Voors AA, Visser ST, et al. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands. Am J Card Drugs. 2010;10:49-54
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-21
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. Br Med J 1995;311:1145-8
   PubMed Web of Science ®Google Scholar
• Sahai H, Kurshid A. Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review. Stat Med 1996;15:1-21
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Alex KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Kymes SM. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases. Ophthalmic Epidemiol 2008;15:76-83
   PubMed Web of Science ®Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500
   PubMed Web of Science ®Google Scholar
• Mullins CD, Blak BT, Akhras KS. Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?. Value Health 2002;5:359-71
   PubMed Web of Science ®Google Scholar